What is the total valuation and payment structure of Sun Pharma's acquisition of Organon?

The acquisition values Organon at about $11.75 billion including debt, and is an all-cash deal in which Sun Pharma will pay $14.00 per share for all outstanding shares of Organon.

What strategic business focus areas does Organon have, and what was its origin?

Organon focuses on women's health, biosimilars, and established medicines, and was spun off from Merck in 2021.

India's Sun Pharma to Buy Organon in $11.75 Billion All-Cash Deal

Apr 26, 2026

India's Sun Pharmaceutical Industries agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion. The transaction grants Sun Pharma full ownership of the Merck spinoff specializing in women's health and biosimilars.

reuters

2026-04-26

India's Sun Pharma to Buy Organon in $11.75 Billion All-Cash Deal

2026-04-28

Sun Pharma to Buy Organon for More Than $11 Billion

2026-06-20

Sun Pharma to acquire Innovcare Lifesciences for $28.7 million

2026-07-29

Indian Shares Seen Muted on Fed Rates Confusion; Sun Pharma Wins Brazil Approval

India's Sun Pharma to Buy Organon in $11.75 Billion All-Cash Deal

FAQ